NASDAQ:SYBX

Synlogic Stock Forecast, Price & News

$3.18
-0.08 (-2.45 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.05
$3.28
50-Day Range
$3.18
$4.39
52-Week Range
$1.78
$5.11
Volume425,484 shs
Average Volume188,400 shs
Market Capitalization$166.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
30 days | 90 days | 365 days | Advanced Chart
Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.


Synlogic logo

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

408th out of 2,215 stocks

Pharmaceutical Preparations Industry

193rd out of 867 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic
or view top-rated stocks.

What stocks does MarketBeat like better than Synlogic?

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synlogic wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synlogic?

Synlogic saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 558,500 shares, an increase of 26.6% from the June 15th total of 441,300 shares. Based on an average trading volume of 421,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.5% of the company's shares are short sold.
View Synlogic's Short Interest
.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Synlogic
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) released its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.03.
View Synlogic's earnings history
.

How has Synlogic's stock been impacted by Coronavirus?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 106.5% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19
.

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic shares reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

5 brokerages have issued 12-month target prices for Synlogic's stock. Their forecasts range from $3.26 to $15.00. On average, they anticipate Synlogic's stock price to reach $10.82 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price.
View analysts' price targets for Synlogic
or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMSc, Pres, CEO & Director (Age 45, Pay $811.3k)
  • Mr. Antoine Awad, Chief Operating Officer (Age 41, Pay $518.42k)
  • Dr. Richard J. Riese M.D., Ph.D., Chief Medical Officer (Age 58, Pay $571.32k)
  • Dr. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder (Age 55)
  • Mr. Gregg D. Beloff, Interim Chief Financial Officer (Age 53)
  • Dr. David L. Hava, Chief Scientific Officer (Age 46)
  • Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
  • Mr. Daniel Rosan, Sr. VP, Head of Fin. & Investor Relations
  • Mr. Michael Conlon, VP of Corp. Devel.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $3.18.

How much money does Synlogic make?

Synlogic has a market capitalization of $166.54 million and generates $550,000.00 in revenue each year. The biotechnology company earns $-59,170,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 72 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

Where are Synlogic's headquarters?

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.